NRX Pharmaceuticals, Inc. Income (Loss) from Continuing Operations, Per Diluted Share
NRX Pharmaceuticals, Inc. (NRXP) reported Income (Loss) from Continuing Operations, Per Diluted Share of -$0.60 per share for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2023-03-31
- NRX Pharmaceuticals, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2022-09-30 was -$0.14.
- NRX Pharmaceuticals, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2022-06-30 was -$0.11.
- NRX Pharmaceuticals, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2021-09-30 was -$0.72.
- NRX Pharmaceuticals, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2021-06-30 was -$6.43.
- NRX Pharmaceuticals, Inc. income (loss) from continuing operations, per diluted share for fiscal 2022 was -$0.60.
- NRX Pharmaceuticals, Inc. income (loss) from continuing operations, per diluted share for fiscal 2021 was -$7.44.
- NRX Pharmaceuticals, Inc. income (loss) from continuing operations, per diluted share for fiscal 2020 was -$1.51.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 3 month as first filed | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month as first filed | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month as first filed | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | -$0.60 10-K · filed 2023-03-31 | ||||||
| 2022-09-30 | -$0.14 10-Q · filed 2022-11-14 | -$0.45 10-Q · filed 2022-11-14 | |||||
| 2022-06-30 | -$0.11 10-Q · filed 2022-08-15 | -$0.32 10-Q · filed 2022-08-15 | |||||
| 2021-12-31 | -$7.44 10-K · filed 2023-03-31 | ||||||
| 2021-09-30 | -$0.72 10-Q · filed 2022-11-14 | -$0.40 10-Q · filed 2021-11-15 | -$7.36 10-Q · filed 2022-11-14 | -$7.35 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | -$6.43 10-Q · filed 2022-08-15 | -$6.51 10-Q · filed 2021-08-16 | -$7.63 10-Q · filed 2022-08-15 | -$7.68 10-Q · filed 2021-08-16 | |||
| 2020-12-31 | -$1.51 10-K · filed 2022-03-31 | ||||||
| 2020-09-30 | -$0.15 10-Q/A · filed 2022-08-12 | -$0.20 10-Q/A · filed 2022-08-12 | |||||
| 2020-06-30 | -$0.04 10-Q/A · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |